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The incidence of hypertension and attendant biological disorders (loss of arterial 
wall elasticity, endothelial dysfunction, insulin resistance) increases with age and so 
does the frequency of cardiovascular complications. Women have a lower incidence of 
hypertension and a later—by an average of 10 years—onset of cardiovascular complica-
tions. During the premenopausal years, women seem to be relatively protected from 
cardiovascular events, in part through the effects of estrogen on endothelial function and 
lipid profile. After menopause however, the incidence of cardiovascular events tends to 
become similar in both genders, and the severity of such events, in terms of morbidity 
and mortality, is actually higher in women. The role of hormone replacement for car-
diovascular protection has been shown to offer no long-term benefits: indeed, despite 
improvement in surrogate endpoints (endothelial function, lipid profile), in long-term 
prospective randomized trials there was no advantage in outcomes, possibly because 
benefits are offset by the thrombogenic and carcinogenic properties of estrogen.
Over age 65 the prevalence of hypertension can reach more than 50%. Systolic 
hypertension predominates, but is itself an important risk factor and marker of car-
diovascular complications. Special considerations affecting choice of antihypertensive 
agents for elderly patients include knowledge of the normal pathophysiologic alterations 
of aging, assessment of coexisting diseases or target organ complications, consideration 
of the pharmacodynamics and kinetics of each class of antihypertensive agents and 
potential drug interactions when treating the frequently coexisting diseases, such as 
diabetes mellitus, chronic obstructive pulmonary disease, arthritis, etc.
Contrary to previous assumptions, elderly hypertensives are not resistant to newer 
antihypertensive agents such as angiotensin-converting enzyme inhibitors (ACEIs) 
or angiotensin II type 1 receptor blockers (ARBs), and in fact appear to respond 
to lower doses with incidence of side-effects generally similar to that of younger 
individuals. ACEIs, ARBs and calcium channel blockers seem to have several ad-
vantages in comparison to older antihypertensive agents in this population, mostly 
because of lack of metabolic disturbances and of central nervous system-mediated 
side-effects (drowsiness, forgetfulness, fatigue etc) that adversely affect the quality 
of life of these patients. The newest antihypertensive drug class, direct renin inhibi-
tors (DRI), whose first member, aliskiren, has recently become available, has not yet 
been studied specifically in elderly hypertensives. However, in view of its mechanism 
of action, it would be expected to have a pharmacologic profile essentially similar to 
that of ACEIs and ARBs.
Evidence of the value of pharmacologic therapy in elderly patients with isolated 
systolic hypertension (ISH) was first provided in 1992 by the Systolic Hypertension in 
the Elderly Program (SHEP). However, as the BP treatment in those years was based 
mostly on thiazide diuretics, the benefits of BP lowering came at the price of significant 
adverse metabolic effects, including hypokalemic, hyperuricemia and increased rate of 
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new-onset type 2 diabetes mellitus, which required additional 
therapeutic interventions.
The question of whether patients over age 80 may benefit 
from antihypertensive treatment was recently answered by the 
Hypertension in the Very Elderly Trial (HYVET), published 
in 2008. Treatment with indapamide, in most cases in combina-
tion with perindopril, showed within 2 years reductions in the 
rate of stroke and heart failure by 30% and 64%, respectively 
and reduction in death from any cause by 21%. These data 
demonstrate that benefits of antihypertensive therapy out-
weigh the risks even in patients of advanced age.
In conclusion, it is now well established that pharmacologic 
interventions to lower elevated blood pressure are safe and 
effective in all ages, even for patients with multiple comor-
bidities. Concern about adverse drug interactions has been an 
important limitation in the past, but has been alleviated with 
the advent of newer, safer classes of antihypertensive agents. 
The wide array of novel available drugs permits selection 
of agents that will not interfere with the pathophysiology or 
pharmacotherapy of commonly coexisting conditions, such 
as diabetes, chronic obstructive pulmonary disease or mus-
culoskeletal disorders.
